PUMA BIOTECHNOLOGY INC's ticker is PBYI and the CUSIP is 74587V107. A total of 136 filers reported holding PUMA BIOTECHNOLOGY INC in Q4 2015. The put-call ratio across all filers is 0.49 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2018 | $360,000 | -20.4% | 6,090 | -8.4% | 0.00% | -33.3% |
| Q1 2018 | $452,000 | -54.8% | 6,646 | -34.4% | 0.00% | -57.1% |
| Q4 2017 | $1,001,000 | +241.6% | 10,129 | +314.1% | 0.01% | +250.0% |
| Q3 2017 | $293,000 | +38.9% | 2,446 | +1.3% | 0.00% | +100.0% |
| Q2 2017 | $211,000 | +3.9% | 2,414 | -20.4% | 0.00% | 0.0% |
| Q3 2016 | $203,000 | +76.5% | 3,031 | -21.2% | 0.00% | 0.0% |
| Q2 2016 | $115,000 | +16.2% | 3,848 | +13.7% | 0.00% | 0.0% |
| Q1 2016 | $99,000 | -49.7% | 3,383 | +34.4% | 0.00% | 0.0% |
| Q4 2015 | $197,000 | +68.4% | 2,518 | +62.5% | 0.00% | 0.0% |
| Q3 2015 | $117,000 | -10.7% | 1,550 | +37.7% | 0.00% | 0.0% |
| Q2 2015 | $131,000 | -32.5% | 1,126 | +37.0% | 0.00% | -50.0% |
| Q1 2015 | $194,000 | +25.2% | 822 | +0.1% | 0.00% | +100.0% |
| Q4 2014 | $155,000 | -29.2% | 821 | -10.7% | 0.00% | -50.0% |
| Q3 2014 | $219,000 | +236.9% | 919 | -6.4% | 0.00% | +100.0% |
| Q2 2014 | $65,000 | – | 982 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| GREAT POINT PARTNERS LLC | 1,300,000 | $13,338,000 | 2.17% |
| Camber Capital Management LP | 2,555,000 | $26,214,000 | 0.92% |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 3,959,741 | $40,627,000 | 0.80% |
| Palo Alto Investors LP | 1,373,897 | $14,096,000 | 0.74% |
| Sofinnova Investments, Inc. | 629,650 | $6,460,000 | 0.38% |
| RICE HALL JAMES & ASSOCIATES, LLC | 604,937 | $6,207,000 | 0.22% |
| J. Goldman & Co LP | 238,617 | $2,448,000 | 0.12% |
| GLOBEFLEX CAPITAL L P | 55,027 | $565,000 | 0.12% |
| FRED ALGER MANAGEMENT, LLC | 3,416,003 | $35,048,000 | 0.09% |
| JUPITER ASSET MANAGEMENT LTD | 728,440 | $7,474,000 | 0.08% |